However, ACE inhibitors interrupt bradykinin breakdown, which in turn potentially enhances nitric oxide and prostacyclin mechanisms.
ARBs selectively prevent the binding of angiotensin II to the angiotensin type 1 (AT (1) ) receptor while leaving the potentially beneficial effects of the AT (2) receptor unaffected.